Other languages RenovoRx, Inc.

Equities

RNXT

US75989R1077

Delayed Nasdaq Other stock markets 03:06:23 2024-07-08 pm EDT			5-day change	1st Jan Change
1.19 ^USD	+4.85%		+3.48%	-48.03%

Jun. 26	University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial	CI
Jun. 10	RenovoRx, Inc. Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial	Jun. 26
RenovoRx, Inc. Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships	Jun. 09
RenovoRx, Inc. Announces Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential	May. 21
RenovoRx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting	Apr. 16
RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01
RenovoRx, Inc. Announces Executive Changes, Effective March 1, 2024	Feb. 23
RenovoRx, Inc. Appoints Ronald B. Kocak as Principal Accounting and Financial Officer	Feb. 09
RenovoRx Raises $6.1 Million From Private Placement; Shares Rise	Jan. 29
Renovorx, Inc. Announces Demise of David Diamond as Lead Independent Director, Chair of the Audit Committee and Member of the Compensation Committee	Jan. 02
Renovorx Engages Oklahoma University Health as First Clinical Site in Preparation for the Pivotal Phase Iiiougar Clinical Trial in Bile Duct Cancer	Dec. 21
RenovoRx, Inc. Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform	Dec. 13
Renovorx Appoints Michel Ducreux as Scientific Advisory Board	Nov. 16
RenovoRx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
RenovoRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16
Renovorx and Imugene Announces Researchcollaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion Platform	23-07-20
RenovoRx, Inc Announces New Positive Interim Phase III Data Demonstrating RenovoGem(TM) Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer	23-06-29
Top Premarket Gainers	23-06-28
RenovoRx, Inc. Appoints Margaret A.Tempero, M.D., to Scientific Advisory Board	23-06-20
Renovorx, Inc. Initiates Patient Enrollment At University of Texas Southwestern Medical Center for Pivotal Phase III Tiger-Pac Clinical Trial	23-06-01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages RenovoRx, Inc.

Equities

RNXT

US75989R1077

Other languages

Filters